Table 3.

Events in statin recommendation classifications stratified by CCTA.

		Hard ASCVD			MACCE
	Total	Events ( %)	Event Rate per 1000 Person-Yrs	HR (95 % CI)	Events ( %)	Event Rate per 1000 Person-Yrs	HR (95 % CI)
No plaque
Statin not recommended	2537	5 (0.2 %)	0.6 (0.2–1.4)	1 (reference)	6 (0.2 %)	0.7 (0.3–1.6)	1 (reference)
Moderate-intensity statin	1623	5 (0.3 %)	0.9 (0.4–2.2)	2.1 (0.3–13.2)	6 (0.4 %)	1.1 (0.5–2.5)	2.7 (0.5–14.3)
High-intensity statin	147	0 (0.0 %)	0	–	0 (0.0 %)	0	–
Non-obstructive CAD
Statin not recommended	767	9 (1.2 %)	3.5 (1.8–6.6)	1 (reference)	15 (2.0 %)	5.8 (3.5–9.5)	1 (reference)
Moderate-intensity statin	1813	32 (1.8 %)	5.4 (3.9–7.7)	1.0 (0.4–2.6)	60 (3.3 %)	10.2 (7.9–13.1)	1.4 (0.7–2.9)
High-intensity statin	239	6 (2.5 %)	8.1 (3.6–17.9)	1.4 (0.3–6.1)	9 (3.8 %)	12.1 (6.3–23.1)	1.9 (0.7–5.4)
Obstructive CAD
Statin not recommended	133	3 (2.3 %)	6.5 (2.1–20.2)	1 (reference)	7 (5.3 %)	15.3 (7.3–31.8)	1 (reference)
Moderate-intensity statin	504	16 (3.2 %)	10.0 (6.1–16.3)	1.5 (0.3–7.0)	52 (10.3 %)	32.5 (24.9–42.4)	1.9 (0.8–4.8)
High-intensity statin	97	7 (7.2 %)	26.9 (13.0–56.0)	3.6 (0.5–27.0)	15 (15.5 %)	57.7 (35.3–94.4)	3.4 (1.0–11.4)

Adjusted for age, sex, smoking, systolic pressure, fasting plasma glucose, low-density lipoprotein cholesterol, coronary artery calcium score, and aspirin use before CCTA.

CCTA, coronary computed tomography angiography; ASCVD, atherosclerotic cardiovascular disease; MACCE, major adverse cardiac and cerebrovascular event; CI, confidence interval; HR, hazard ratio; CAD, coronary artery disease.